A Phase I, Two-Part, Multi-Center, Non Randomized, Open-Label, Multiple Dose First-In-Human Study Of DS-6051B, An Oral ROS1 And NTRK Inhibitor, In Subjects With Advanced Solid Tumors

UCI-14-39
NCT02279433
Cancer - Colon, Cancer - Lung, Cancer - Pancreas, Cancer - Soft Tissue
Sai-Hong Ignatius Ou
Open
Treatment
DS-6051B
I
Adult
Local

For information about cancer clinical trials at the UC Irvine Health Chao Family Comprehensive Cancer Center, call toll-free 877-UC-STUDY (877-827-8839) or email ucstudy@uci.edu.